ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts.

ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts.

ReNewVax’s Chief Scientific Officer Dr Marie O’Brien is published in this autumn’s edition of Drug Target Review, sharing insights into our quest for a universal pneumococcal vaccine.

Since spinning out of the University of Liverpool, ReNewVax has started to build its scientific team and progressed its vaccine programme RVX-001 towards regulatory studies that will allow clinical trials to begin. CSO Dr. Marie O’Brien and CEO Dr. Neil Murray reflect on what the company has achieved to date and what the future has in store.

This month, European Pharmaceutical Review features a piece from ReNewVax’s Chief Executive Dr. Neil Murray for its Formulation issue. 

This month, North West Business Insider has named ReNewVax as one of thirty businesses across the region carrying out exciting work in their sectors. The Most Exciting Companies list features a range of companies shaking up their sectors, whether it be manufacturing, retail or technology.  

We’re thrilled to announce that ReNewVax has been shortlisted as one of the finalists to present a pitch at the 2023 BIO International Convention in Boston, Massachusetts. 

World Immunization Week, celebrated in the last week of April, aims to highlight the collective action needed to protect people from vaccine-preventable diseases. Here, our chief scientific officer Dr Marie O’Brien discusses the importance of the event and how ReNewVax is contributing.

World Immunization Week, celebrated in the last week of April, aims to highlight the collective action needed to protect people from vaccine-preventable diseases. Here, our chief scientific officer Dr Marie O’Brien discusses the importance of the event and how ReNewVax is contributing.

Our chief scientific officer Dr Marie O’Brien is featured in the April/May edition of Laboratory News discussing ReNewVax’s RVX-001 pneumococcal vaccine program.